{"analyses":[{"ciLowerLimit":"0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.7","estimateComment":"The adjusted difference and its 95% CI were calculated using the Wald method from Cochran-Mantel Haenszel test to account for the randomization schedule stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".059","pValueComment":"p-value was calculated from a stratified Cochran-Mantel Haenszel test accounting for the randomization schedule stratification factors.","paramType":"Adjusted difference","paramValue":"1.5","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"3.1","value":"1.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"1.6","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), per RECIST v1.1, as determined by the investigator. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\\<)10 millimeters (mm).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until the first documentation of best overall response (up to 22 months)","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}